VBI Vaccines Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIV research report →
Price Chart
About the company
VBI Vaccines Inc. is a biopharmaceutical firm dedicated to the development and commercialization of vaccines, targeting both infectious diseases and immuno-oncology. Among its commercial offerings is Sci-B-Vac, a prophylactic vaccine designed to prevent hepatitis B (HBV).
- CEO
- Jeffery R. Baxter FCMA
- IPO
- 2010
- Employees
- 131
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on VBIV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.87M
- P/E
- -0.01
- Fwd P/E
- 0.93
- PEG
- -0.00
- P/S
- 0.22
- P/B
- 0.14
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
- Gross Margin
- -66.98%
- Op Margin
- -637.08%
- Net Margin
- -1069.29%
- ROE
- -258.99%
- ROIC
- -86.51%
Latest fiscal year · YoY change
- Revenue
- $8.68M+702.4%
- Gross Profit
- $-5,815,000+43.0%
- Op Income
- $-55,311,000
- Net Income
- $-92,836,000+34.1%
- EPS
- $-5.96+63.6%
- OCF Growth
- +17.4%
- FCF Growth
- +20.9%
- 52W High
- $1.35
- 52W Low
- $0.06
- 50D MA
- $0.57
- 200D MA
- $0.60
- Beta
- 2.17
- RSI (14)
- 22
- Avg Volume
- 8.39M
No earnings-call transcripts are available for VBIV yet.
- Free Float
- 93.2%
- Shares Outstanding
- 28.68M
- Float Shares
- 26.73M
of shares held by institutions
37 13F filers
Buy/sell ratio 11.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 108.59K | 0 |
| Baystate Wealth Management LLC | 16 | 0 |
Held by 4 ETFs
Biggest fund positions in VBIV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 23 | DeWilde Michel | other | 35,000 |
| Jul 27, 23 | Braga Damian | other | 35,000 |
| Jul 27, 23 | Baxter Jeff | other | 70,000 |
| Jul 27, 23 | Cordeiro Joanne | other | 35,000 |
| Jul 27, 23 | Beattie Nell | other | 52,500 |
| Jul 27, 23 | HIMES VAUGHN B | other | 35,000 |
| Jul 27, 23 | Mazaltov Avi | other | 52,500 |
| Jul 27, 23 | Diaz-Mitoma Francisco | other | 52,500 |
| Jul 27, 23 | GILLIS STEVEN | other | 52,500 |
| Jul 27, 23 | Dillman John Robert | other | 52,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VBIV coverage
Recent articles, reports, and earnings notes.
No research on VBIV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBIV report →VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
businesswire.com · Nov 15
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
investorplace.com · Aug 6
VBI Vaccines Announces Results of Annual General Meeting
businesswire.com · Jun 25
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
businesswire.com · May 29
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
businesswire.com · May 22
VBI Vaccines Reports First Quarter 2024 Financial Results
businesswire.com · May 15
VBI Vaccines Reports Full Year 2023 Financial Results
businesswire.com · Apr 16
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
businesswire.com · Apr 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.